The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30143-7 · Cited by 1,635
Hypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
The molecular origin of DNA-drug specificity in netropsin and distamycin.
Kopka, M. L., Yoon, C. N., Goodsell, D. S., Pjura, P. E., & Dickerson, R. E. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.5.1376 · Cited by 903
Glutathione-Associated Enzymes In Anticancer Drug Resistance
Tew, K. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3143 · Cited by 856
Zimmer, C., & Wähnert, U. (1986) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(86)90005-2 · Cited by 764
Cancer principles and practice of oncology
Kerin, M. J. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)90012-8 · Cited by 739
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
CHRISTENSSON, A., LAURELL, C., & LILJA, H. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb19466.x · Cited by 641
Integrins as therapeutic targets: lessons and opportunities
Cox, D., Brennan, M., & Moran, N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3266 · Cited by 456
Knauf, W. U., Lissichkov, T., Aldaoud, A., Liberati, A. M., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranova-Marinova, V. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8389 · Cited by 444
DNA minor groove binders as potential antitumor and antimicrobial agents
Baraldi, P. G., Bovero, A., Fruttarolo, F., Preti, D., Tabrizi, M. A., Pavani, M. G., & Romagnoli, R. (2004) · Medicinal Research Reviews · doi:10.1002/med.20000 · Cited by 376
Prodrugs for improving tumor targetability and efficiency
Mahato, R., Tai, W., & Cheng, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.02.002 · Cited by 353
Huang, Z.-Z., Chen, C., Zeng, Z., Yang, H., Oh, J., Chen, L., & C. Lu, S. (2001) · The FASEB Journal · doi:10.1096/fj.00-0445fje · Cited by 243
Integrin Targeted Delivery of Chemotherapeutics
Chen, K., & Chen, X. (2011) · Theranostics · doi:10.7150/thno/v01p0189 · Cited by 242
Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Singh, Y., Palombo, M., & Sinko, P. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132997 · Cited by 242
Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
Duan, J.-X., Jiao, H., Kaizerman, J., Stanton, T., Evans, J. W., Lan, L., Lorente, G., Banica, M., Jung, D., Wang, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701028q · Cited by 239
Lewis, A. D., Hayes, J. D., & Wolf, C. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1283 · Cited by 223
Complexes of the Minor Groove of DNA
Geierstanger, B. H., & Wemmer, D. E. (1995) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.bb.24.060195.002335 · Cited by 197
Sequence selectivity of DNA covalent modification
Warpehoski, M. A., & Hurley, L. H. (1988) · Chemical Research in Toxicology · doi:10.1021/tx00006a001 · Cited by 182
Site-Specific, Sustained Release of Drugs to the Brain
Bodor, N., Farag, H. H., & Brewster, M. E. (1981) · Science · doi:10.1126/science.7313698 · Cited by 181
Nordsmark, M., Bentzen, S. M., & Overgaard, J. (1994) · Acta Oncologica · doi:10.3109/02841869409098433 · Cited by 180
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
Senter, P. D., & Springer, C. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00206-x · Cited by 178
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility
Williams, E. M., Little, R. F., Mowday, A. M., Rich, M. H., Chan-Hyams, J. V. E., Copp, J. N., Smaill, J. B., Patterson, A. V., & Ackerley, D. F. (2015) · Biochemical Journal · doi:10.1042/bj20150650 · Cited by 171
Dirven, H. A. A. M., van Ommen, B., & van BLADEREN, P. J. (1994) · PubMed · Cited by 163
Suicide genes for cancer therapy
Portsmouth, D., Hlavatý, J., & Renner, M. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.001 · Cited by 157
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155
Inhibitors of glutathione S-transferases as therapeutic agents
Schultz, M., Dutta, S., & Tew, K. D. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00029-x · Cited by 155
Rationale and applications of lipids as prodrug carriers
Lambert, D. M. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00161-5 · Cited by 148
de Groot, F. M. H., Damen, E. W. P., & Scheeren, H. W. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372634 · Cited by 129
Targeting drugs to the brain by redox chemical delivery systems
Prókai, L., Prókai-Tátrai, K., & Bodor, N. S. (2000) · Medicinal Research Reviews · doi:10.1002/1098-1128(200009)20:5<367::aid-med3>3.0.co;2-p · Cited by 125
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
Dachs, G. U., Hunt, M. A., Syddall, S. P., Singleton, D. C., & Patterson, A. V. (2009) · Molecules · doi:10.3390/molecules14114517 · Cited by 123
The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases
Mahajan, S., & Atkins, W. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4524-6 · Cited by 110
Butturini, E., Cavalieri, E., de Prati, A. C., Darra, E., Rigo, A., Shoji, K., Murayama, N., Yamazaki, H., Watanabe, Y., Suzuki, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020174 · Cited by 107
Chauhan, D., Ray, A., Viktorsson, K., Spira, J., Paba‐Prada, C. E., Munshi, N. C., Richardson, P. G. G., Lewensohn, R., & Anderson, K. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3752 · Cited by 107
Man-Made Cytotoxic Steroids: Exemplary Agents for Cancer Therapy
Bansal, R., & Acharya, P. C. (2014) · Chemical Reviews · doi:10.1021/cr4002935 · Cited by 105
Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates
Marvania, B., Lee, P., Chaniyara, R., Dong, H., Suman, S., Kakadiya, R., Chou, T., Lee, T., Shah, A. K., & Su, T. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.055 · Cited by 104
Glutathione-S-transferase Activates Novel Alkylating Agents
Lyttle, M. H., Satyam, A., Hocker, M. D., Bauer, K. E., Caldwell, C. G., Hui, H. C., Morgan, A. S., Mergia, A., & Kauvar, L. M. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00036a016 · Cited by 100
Testa, U., Pelosi, E., & Peschle, C. (1993) · PubMed · Cited by 97
Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Tietze, L. F., & Schmuck, K. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798194459 · Cited by 96
Synthesis and in Vitro Efficacy of Transferrin Conjugates of the Anticancer Drug Chlorambucil
Beyer, U., Roth, T. F., Schumacher, P., Maier, G., Unold, A., Frahm, A. W., Fiebig, H., Unger, C., & Kratz, F. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9704661 · Cited by 95
Isoenzyme-specific glutathione-S-transferase inhibitors: design and synthesis
Lyttle, M. H., Hocker, M. D., Hui, H. C., Caldwell, C. G., Aaron, D. T., Engqvist-Goldstein, Å. E. Y., Flatgaard, J. E., & Bauer, K. E. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00027a024 · Cited by 90
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
Gilad, Y., Firer, M. A., & Gellerman, G. (2016) · Biomedicines · doi:10.3390/biomedicines4020011 · Cited by 87
McKeage, M. J., Gu, Y., Wilson, W. R., Hill, A. M., Amies, K., Melink, T. J., & Jameson, M. B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-432 · Cited by 77
Morgan, A. S., Sanderson, P. E., Borch, R. F., Tew, K. D., Niitsu, Y., Takayama, T., Hoff, D. D. V., Izbicka, E., Mangold, G. L., Paul, C., et al. (1998) · PubMed · Cited by 76
Bendamustine: something old, something new
Tageja, N., & Nagi, J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1317-x · Cited by 73
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
TLK-286: a novel glutathioneS-transferase-activated prodrug
Tew, K. D. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.8.1047 · Cited by 69
Gu, Y., Patterson, A. V., Atwell, G. J., Chernikova, S. B., Brown, J. M., Thompson, L. H., & Wilson, W. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1209 · Cited by 69
Schomburg, C., Schuehly, W., Costa, F. B. D., Klempnauer, K., & Schmidt, T. J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.02.018 · Cited by 66
Shi, L., Yang, F., Luo, F., Liu, Y., Zhang, F., Zou, M., & Liu, Q. (2016) · Tumor Biology · doi:10.1007/s13277-016-5251-3 · Cited by 64
Tercel, M., Lee, A. E., Hogg, A., Anderson, R. F., Lee, H. H., Siim, B. G., Denny, W. A., & Wilson, W. R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010202l · Cited by 63
A novel kind of antitumour drugs using sulfonamide as parent compound
Huang, Z. R. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01285-5 · Cited by 62
Borch, R. F., Liu, J., Schmidt, J. P., Marakovits, J. T., Joswig, C., Gipp, J. J., & Mulcahy, R. T. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001020 · Cited by 61
A Novel Design Strategy for Stable Metal Complexes of Nitrogen Mustards as Bioreductive Prodrugs
Parker, L. L., Lacy, S. M., Farrugia, L. J., Evans, C., Robins, D. J., O’Hare, C. C., Hartley, J. A., Jaffar, M., & Stratford, I. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049866w · Cited by 60
Chen, W., Han, Y., & Peng, X. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201400090 · Cited by 59
Design, synthesis and biological evaluation of estradiol–chlorambucil hybrids as anticancer agents
Gupta, A. K., Saha, P., Descôteaux, C., Leblanc, V., Asselin, É., & Bérubé, G. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.053 · Cited by 56
Kakadiya, R., Dong, H., Kumar, A., Dodia, N. M., Zhang, X., Chou, T., Lee, T., Shah, A. K., & Su, T. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.061 · Cited by 56
Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy
Fan, M., Liang, X., Li, Z., Wang, H., Yang, D., & Shi, B. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.08.013 · Cited by 54
Tietze, L. F., & Krewer, B. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00856.x · Cited by 53
Cellular Response to a Glutathione S-Transferase P1-1 Activated Prodrug
Rosario, L. A., O’Brien, M. L., Henderson, C. J., Wolf, C. R., & Tew, K. D. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12153-0 · Cited by 53
Gilad, Y., Noy, E., Senderowitz, H., Albeck, A., Firer, M. A., & Gellerman, G. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.020 · Cited by 53
Dual‐drug RGD conjugates provide enhanced cytotoxicity to melanoma and non‐small lung cancer cells
Gilad, Y., Noy, E., Senderowitz, H., Albeck, A., Firer, M. A., & Gellerman, G. (2015) · Biopolymers · doi:10.1002/bip.22800 · Cited by 53
The mechanism of activation of 4-hydroxycyclophosphamide
Borch, R. F., & Millard, J. A. (1987) · Journal of Medicinal Chemistry · doi:10.1021/jm00385a029 · Cited by 48
Volpato, M., Abou-Zeid, N., Tanner, R. W., Glassbrook, L. T., Taylor, J. P., Stratford, I. J., Loadman, P. M., Jaffar, M., & Phillips, R. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0519 · Cited by 48
Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon, C., Maddison, K., LoCastro, L., & Borch, R. F. (1987) · PubMed · Cited by 44
High Dose Chlorambucil in the Treatment of Lymphoid Malignancies
Nicolle, A., Proctor, S. J., & SUMMERFIELD, G. P. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001595704 · Cited by 44
Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives
Reux, B., Weber, V., Galmier, M., Borel, M., Madesclaire, M., Madelmont, J., Débiton, E., & Coudert, P. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.038 · Cited by 43
Zhao, M., Ren, H., Chang, J. K., Zhang, D., Yang, Y., He, Y., Qi, C., & Zhang, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.068 · Cited by 43
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo
Strese, S., Wickström, M., Fuchs, P. F., Fryknäs, M., Gerwins, P., Dale, T., Larsson, R. L., & Gullbo, J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.026 · Cited by 37
The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells
Hu, C.-Y., Yi, C.-Q., Hao, Z., Cao, S., Li, H., Shao, X., Zhang, J., Qiao, T., & Fan, D. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.962 · Cited by 37
Tercel, M., Wilson, W. R., Anderson, R. F., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9507791 · Cited by 35
Bacherikov, V. A., Chou, T., Dong, H.-J., Zhang, X., Chen, C.-H., Lin, Y., Tsai, T., Lee, R.-Z., Liu, L. F., & Su, T. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.03.057 · Cited by 34
Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy
Niculescu‐Duvaz, I., & Springer, C. J. (1995) · Current Medicinal Chemistry · doi:10.2174/092986730203220223143057 · Cited by 33
A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency
Liu, C., Ding, H., Li, X., Pallasch, C. P., Hong, L., Guo, D., Chen, Y., Wang, D., Wang, W., Wang, Y., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404580 · Cited by 33
Helsby, N. A., Atwell, G. J., Yang, S., Palmer, B. D., Anderson, R. F., Pullen, S. M., Ferry, D. M., Hogg, A., Wilson, W. R., & Denny, W. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0498699 · Cited by 32
Berglund, Å., Ullén, A., Lisyanskaya, A. S., Орлов, С. В., Hagberg, H., Tholander, B., Lewensohn, R., Nygren, P., Spira, J., Harmenberg, J., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0299-2 · Cited by 32
Wilson, W. R., Tercel, M., Anderson, R. F., & Denny, W. A. (1998) · PubMed · Cited by 30
Glufosfamide as a new oxazaphosphorine anticancer agent
Mazur, L., Opydo‐Chanek, M., & Stojak, M. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328345e1e0 · Cited by 30
Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds
Lesniewska, M. A., & Muszalska, I. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.011 · Cited by 30
Han, T., Tian, K., Pan, H., Liu, Y., Xu, F., Li, Z., Uchita, T., Gao, M., Hua, H., & Li, D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.088 · Cited by 30
Shervington, L. A., Smith, N., Norman, E., Ward, T. H., Phillips, R. M., & Shervington, A. A. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.11.014 · Cited by 28
Xu, Y., Gu, X., Peng, S., Fang, J., Zhang, Y., Huang, D., Chen, J., & Gao, K. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.001 · Cited by 28
A polyphosphoester conjugate of melphalan as antitumoral agent
Bogomilova, A., Höhn, M., Günther, M., Herrmann, A., Troev, K. D., Wagner, E., & Schreiner, L. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.007 · Cited by 27
Lin, S., Li, Y., Zheng, Y., Luo, L., Sun, Q., Ge, Z., Cheng, T., & Li, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.055 · Cited by 27
Bashari, O., Redko, B., Cohen, A., Luboshits, G., Gellerman, G., & Firer, M. A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.040 · Cited by 27
Gellerman, G., Baskin, S., Luboshits, G., Gilad, Y., & Firer, M. A. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835bb17a · Cited by 26
“Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide
Gilad, Y., Firer, M. A., Rozovsky, A., Ragozin, E., Redko, B., Albeck, A., & Gellerman, G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.073 · Cited by 25
Chandor-Proust, A., Dijols, S., Ramassamy, B., Frapart, Y., Mansuy, D., Stuehr, D. J., Helsby, N. A., & Boucher, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7004234 · Cited by 24
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Cj, S., & Niculescu‐Duvaz, I. (1995) · PubMed · Cited by 23
Singh, R. K., Prasad, D. N., & Bhardwaj, T. (2014) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2013.12.008 · Cited by 22
Self-citationXie, R., Tang, P., & Yuan, Q. (2017) · MedChemComm · doi:10.1039/c7md00476a · Cited by 20
Synthesis of androstene oxime-nitrogen mustard bioconjugates as potent antineoplastic agents
Acharya, P. C., & Bansal, R. (2017) · Steroids · doi:10.1016/j.steroids.2017.04.005 · Cited by 17
Prolidase-activated prodrug for cancer chemotherapy
Bielawska, A., Bielawski, K., Chrzanowski, K., & Wołczyński, S. (2000) · Il Farmaco · doi:10.1016/s0014-827x(00)00095-1 · Cited by 13
Jin, G. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01229-6 · Cited by 10
DNA Minor Groove Binders as Therapeutic Agents
Withers, J. M., Padroni, G., Pauff, S. M., Clark, A. W., Mackay, S. P., & Burley, G. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12561-2 · Cited by 8
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery
Chiodi, D., & Ishihara, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02015 · Cited by 263
Teka, T., Zhang, L., Ge, X., Li, Y., Han, L., & Yan, X. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113128 · Cited by 216
Metadata
- Authors
- Singh, R. K., Kumar, S., Prasad, D. N., & Bhardwaj, T. R.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 151
- Pages
- 401-433
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2795464319
- Cited by
- 282
- References
- 103
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.